The forward P/E of 14.8x implies the market expects earnings growth of roughly 8% annually, which aligns with recent revenue acceleration but remains below the double-digit growth of peers like BSX and SYK. The EV/EBITDA discount of roughly 50% versus Stryker may reflect GEHC's lower gross margins and higher leverage, but it also suggests that if the company can sustain its recent 5.8% revenue growth, the valuation could re-rate upward. Investors should monitor whether the discount narrows as free cash flow volatility subsides.

Excluding the 2025Q4 anomaly, gross margin has been remarkably stable around 40-42%, and operating margin has hovered between 11.6% and 15.1% over the past ten quarters. This suggests that the underlying profitability is more consistent than the headline numbers imply, and the 2025Q4 spike likely reflects a one-time benefit such as a favorable product mix or a settlement. Net margin, however, has been more volatile due to tax items, as seen in 2025Q4's 3.9% versus 2024Q4's 13.5%, so investors should focus on operating margin as the cleaner measure of earning power.

The stability of ROIC around 3% suggests that the company is not compounding returns on invested capital, despite a growing equity base from retained earnings. The low ROIC relative to peers like Stryker (11.1%) and Boston Scientific (8.8%) may reflect the heavy goodwill load from acquisitions, which inflates the capital base without correspondingly higher operating income. The recent uptick in revenue growth has not yet translated into higher ROIC, so investors should watch whether operating margin expansion can drive returns higher over the next few quarters.

The CCC has been relatively stable, but the components show that GEHC extends payment terms to suppliers (DPO ~95 days) while collecting from customers in about 80 days, which is typical for medical equipment makers. However, the swings in working capital, such as the $478 million outflow in 2024Q2, have caused free cash flow to be highly uneven, with FCF margin ranging from -11.7% to 19.6%. This suggests that the company's cash conversion is not as efficient as its asset turnover of 0.14x implies, and investors should monitor whether management can smooth these swings through better inventory and receivables management.

The D/EBITDA ratio is high, but it is distorted by the low EBITDA in certain quarters, such as 2026Q1 when it hit 15.8x. On a trailing basis, the ratio is likely closer to 8-10x, which is still elevated compared to peers like Stryker (0.73x D/E) and Boston Scientific (0.51x). Interest coverage of 7.1x in 2026Q2 provides a comfortable cushion, but the company's thin liquidity buffer (current ratio near 1.0) and high goodwill suggest that refinancing risk could emerge if earnings deteriorate. Investors should monitor the trajectory of EBITDA and debt levels to ensure coverage remains stable.

The current ratio of 1.02 in 2026Q2 suggests that current assets barely cover current liabilities, and the quick ratio of 0.72 indicates that inventory is a significant component of current assets. This leaves little room for a sudden cash crunch, especially given the volatility in free cash flow. However, the company has access to credit markets, as evidenced by its debt levels, and its interest coverage remains adequate. Investors should monitor whether the company can maintain its dividend and buyback program without straining liquidity, particularly if working capital outflows persist.

The valuation discount is justified by GEHC's lower ROIC (2.9% vs. peers' 6-15%) and higher leverage (D/E 0.92 vs. peers' 0.07-0.73). However, GEHC's net margin of 10.8% is comparable to Stryker's 12.9% and Boston Scientific's 14.4%, indicating that the profitability gap is not as wide as the valuation gap suggests. The discount may also reflect the market's concern about the company's ability to grow revenue at the same pace as its more innovative peers, given its mature product portfolio. If GEHC can sustain its recent growth acceleration and improve working capital efficiency, the valuation gap could narrow.